Navigation Links
NEURO-BIOTECH CORPORATION: Updates and latest developments
Date:11/1/2010

NEURO-BIOTECH CORPORATION: Updates and latest developments


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
OTC, SmallCap, Biotechnology Click to view news release full screen  

NEURO-BIOTECH CORPORATION: Updates and latest developments

 

BASEL, Switzerland, Nov. 1 /PRNewswire/ - Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB: MRES).

In the first "Update to Shareholders," we advised shareholders of the Company's new direction as well as the list of licensed products ready to be manufactured and distributed.

Subsequently, we revealed the description of two "Blood Tests" by first releasing a scientific account and analysis followed by a "layman's" version with explanations for common understanding.

We have also informed the public, based on official statistics, of the commercial potential of the SymPath test in the American market.

It is now the time to disclose the work done since the first "Update to Shareholders."

Neuro-Biotech has to date, signed confidentiality agreements with various interested parties, including a Spanish group representing the vast majority of hospitals and private clinics in Spain. This group has shown a particular appreciation for the distribution of all our blood tests. Seeing that there is language and historical ties, all private clinics and private hospitals located in South America will be automatically granted access.

Now if you review the list of licenses your company owns, you will notice that the last four licenses (13, 14, 15, 16), are what we call Neuroceuticals™. It's actually tablets to be sold in pharmacies, that will be classified and sold as "food supplements," in order to accelerate the market penetration. There will be two concentrations; one sold "over the counter," and the other with a medical prescription.

This fact is mentioned due to the ongoing actual negotiations with another Spanish party that controls networks of pharmacies across the country and in South America. Very soon, similar negotiations will open with large chains of pharmacies in the United States and Canada.

We already have on hand a first order from Egypt, and we expect to conclude and receive other sales orders in the near future. The manufacturing of these tablets do not require significant capital investments such as laboratories. Fabrication will be assigned to a pharmaceutical company, already identified, responding to all our criteria and quality standards. As for cost, it remains for us to agree on the quantities to achieve economies of scale.

Regarding our "Blood Tests," we also started preliminary discussions with chains of laboratories, in order to first, identify, evaluate and explore potential partnerships. This will avoid us having to invest in our own lab facilities in the short and medium term while ensuring the production of blood test results for health professionals to track their patients. This is exactly the same principle as a blood test ordered by your doctor to know your cholesterol levels.

We also solicited and were contacted by various insurance companies about "SymPath." This test has been the subject of numerous scientific publications and has been evaluated in over 5,000 human subjects with consistent results of 98.8% precision. With this accuracy, the results could be enough to obtain a legal court opinion on a patient's medical status.

The reason why insurance companies have expressed such a considerable interest is economic. As this test accurately measures the patient's condition on a scale, it avoids the sequences of "trial and error," as is currently the case in the beginning of treatment. Therefore, the health professional receiving the test results will immediately be able to precisely diagnose the patient's condition and to prescribe the proper medication.

The immediate consequences, as you can imagine, will be a dramatic reduction of suffering for the patient, his family, his environment and accelerated healing. From a purely economic and social development standpoint, this will certainly lead to a significant reduction in lost workdays, and fewer payments from insurers and employers! Currently, without this test, it is virtually impossible for medical professional specializing in this type of disease, to separate the real from the fake patients. The whole of society will benefit from this.

The Company will continue to provide its shareholders and investors with timely updates.

For more information, do not hesitate to contact us by using the form on our corporate website at neuro-biotechcorp.com. Your request will be transferred to the appropriate person and we will get back to you as soon as possible. Forward Looking Statements This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

CONTACT: <p>Neuro-Biotech Corp.<br/> Dr Claude Poulin<br/> 41 61 500 05 16<br/> <a href="mailto:info@neuro-agora.com">info@neuro-agora.com</a><br/> <a href="http://www.neuro-biotechcorp.com">www.neuro-biotechcorp.com</a></p>


'/>"/>
SOURCE Neuro-Biotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
2. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
3. Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.
4. Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago
5. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
6. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
7. China-Biotics Provides Further Updates on Qingpu New Facility
8. Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition
9. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
10. BioMS updates corporate strategy and adds leading healthcare investment banker
11. BioMS Medical updates University of Alberta equity position
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):